Rituximab,Methotrexate and Lenalidomide in Newly Diagnosed Primary Central Nervous System Lymphoma
Status:
Recruiting
Trial end date:
2026-12-12
Target enrollment:
Participant gender:
Summary
It is a single arm, multicenter, phase 2 study to explore the efficacy and safety study of
R2-MTX chemotherapy（Lenalidomide, Rituximab and Methotrexate）as first-line regimens in the
treatment of newly diagnosed primary central nervous system lymphoma. Objective response rate
is the primary endpoint.
Phase:
Phase 2
Details
Lead Sponsor:
Second Affiliated Hospital, School of Medicine, Zhejiang University